{
  "2019_Pipeline_Status":[
    {
      "Phase": "Phase 1",
      "NCT #": "NCT01677572",
      "Drug Name": "Aducanumab (BIIB037)",
      "Status": "Terminated (based on futility analysis conducted on Phase 3 trials, not based on safety concerns",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "",
      "Geography": ""
    },
    {
      "Phase": "Phase 1",
      "NCT #": "NCT03298672",
      "Drug Name": "NDX-1017",
      "Status": "Completed",
      "Biomarkers": "no",
      "MOA Class": 4,
      "MOA Category": "g",
      "CADRO MOA Category": "",
      "Geography": ""
    },
    {
      "Phase": "Phase 1",
      "NCT #": "NCT03008161",
      "Drug Name": "NPT088",
      "Status": "Completed",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a, b",
      "CADRO MOA Category": "",
      "Geography": ""
    },
    {
      "Phase": "Phase 1",
      "NCT #": "NCT03698695",
      "Drug Name": "THN 201 (donepezil and mefloquine combo)",
      "Status": "Ongoing",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "e",
      "CADRO MOA Category": "D, F?",
      "Geography": 3
    },
    {
      "Phase": "Phase 1",
      "NCT #": "NCT01966666",
      "Drug Name": "TPI-287",
      "Status": "Ongoing",
      "Biomarkers": "No",
      "MOA Class": 3,
      "MOA Category": "b",
      "CADRO MOA Category": "B",
      "Geography": 1
    },
    {
      "Phase": "Phase 1",
      "NCT #": "NCT03056495",
      "Drug Name": "Vorinostat",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "c",
      "CADRO MOA Category": "F (infection/immunity)",
      "Geography": 3
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT03801642",
      "Drug Name": "Dapagliflozin",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": "3?",
      "MOA Category": "d",
      "CADRO MOA Category": "J",
      "Geography": 1
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT02414607",
      "Drug Name": "Elderberry Juice",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "c, f",
      "CADRO MOA Category": "M",
      "Geography": 1
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT02579252",
      "Drug Name": "AADvac1",
      "Status": "Completed",
      "Biomarkers": "CSF",
      "MOA Class": 4,
      "MOA Category": "b",
      "CADRO MOA Category": "B",
      "Geography": ""
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03712787",
      "Drug Name": "ABBV-8E12",
      "Status": "Enrolling by invitation - Extension study",
      "Biomarkers": "no",
      "MOA Class": 4,
      "MOA Category": "b",
      "CADRO MOA Category": "B",
      "Geography": "1, 3, 7"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03639987",
      "Drug Name": "Aducanumab (EVOLVE)",
      "Status": "Terminated (based on futility analysis conducted on Phase 3 trials and not based on safety concerns)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "",
      "Geography": ""
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT02129348",
      "Drug Name": "Lithium",
      "Status": "Recruiting",
      "Biomarkers": "No",
      "MOA Class": 2,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 1
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03062449",
      "Drug Name": "L-Serine",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "c",
      "CADRO MOA Category": "F? M?",
      "Geography": 1
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03649724",
      "Drug Name": "Lupron (Leuprolide Acetate Depot) + ACheI (2014 study showed that in a sub population of female subjects on AchEI, showed cognitive improvement; basis for this current study)",
      "Status": "Not yet recruiting",
      "Biomarkers": "PET",
      "MOA Class": "3?",
      "MOA Category": "d",
      "CADRO MOA Category": "L?",
      "Geography": 1
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03367403",
      "Drug Name": "LY3002813",
      "Status": "Ongoing",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": 1
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03518073",
      "Drug Name": "LY3303560 (zagotenemab)",
      "Status": "Ongoing",
      "Biomarkers": "no",
      "MOA Class": 4,
      "MOA Category": "b",
      "CADRO MOA Category": 2,
      "Geography": "1, 5"
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT03131453",
      "Drug Name": "CNP520 (Umibecestate) (Generation 2 - why still listed as ongoing?)",
      "Status": "Ongoing",
      "Biomarkers": "PET or CSF",
      "MOA Class": 3,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "1, 2, 3, 5, 6, 7"
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT03823404",
      "Drug Name": "COR388",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "f",
      "CADRO MOA Category": "F",
      "Geography": ""
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT01760005",
      "Drug Name": "Gantenerumab & Solanezumab",
      "Status": "Recruiting (changed from ongoing to recruiting)",
      "Biomarkers": "No",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "1, 2, 3, 5, 6, 7"
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT03090516",
      "Drug Name": "Ginkgo Biloba",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 1,
      "MOA Category": "d",
      "CADRO MOA Category": "J, K ?",
      "Geography": 5
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT02719327",
      "Drug Name": "Icosapent ethyl (IPE) (Vascepa)",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "c",
      "CADRO MOA Category": "M",
      "Geography": 1
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT02913664",
      "Drug Name": "Losartan, Amlodipine, Atorvastatin + exercise (all count as 1 agent)",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "f, d",
      "CADRO MOA Category": "K",
      "Geography": 1
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT02351882",
      "Drug Name": "Nabilone",
      "Status": "Completed (success; showed reduced agitation and improvement on MMSE but poorer cognition and sedation vs. placebo)",
      "Biomarkers": "No",
      "MOA Class": 2,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": ""
    },
    {
      "Phase": "Phase 2|Phase 3",
      "NCT #": "NCT03446001",
      "Drug Name": "TRx0237 (LMTX) - using the 4mg BID dose used as the placebo control group in the previous study",
      "Status": "Ongoing",
      "Biomarkers": "PET",
      "MOA Class": 3,
      "MOA Category": "b",
      "CADRO MOA Category": "B",
      "Geography": "1, 3, 4"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT02477800",
      "Drug Name": "Aducanumab (BIIB037)",
      "Status": "Terminated (based on futility analysis not based on safety concerns; follow up visits and closing out study activities are completed)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": ""
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT02484547",
      "Drug Name": "Aducanumab (BIIB037)",
      "Status": "Terminated (based on futility analysis not based on safety concerns; follow up visits and closing out study activities are completed)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": ""
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT01767311",
      "Drug Name": "BAN2401",
      "Status": "Ongoing (status changed from Completed status in 2019)",
      "Biomarkers": "PET or CSF",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "1, 3, 5, 6"
    }
  ]
}